Elisigen has successfully completed dosing for all 20 participants in the North American Phase 1/2a clinical trial of 'NG101'. The company will now monitor long-term safety and efficacy data to establish a solid foundation for subsequent clinical stages.
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.